UWCCC Molecular Tumor Board Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Wisconsin, Madison
About this trial
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Clinically suspected or histologically confirmed solid or hematological malignancy
Undergoing genetic testing of tumor
Ability to understand written informed consent document
Willingness to sign written informed consent document
Disqualifiers
Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee
Trial population
This study will include all patients age ≥18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. It will require each patient to have the ability to understand and willingness to sign a written informed consent document.
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
PMMTB (Precision Medicine Molecular Tumor Board)
Other interventionPMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.
Treatment groups
10,000 Participants
are divided into 1 treatment groupGroup A: PMMTB1 intervention
Trial outcomes
Primary outcomes
1
Frequency of acceptance of molecular tumor board recommendations
How often the molecular tumor board's recommendations are accepted
Time frame
Up to 5 years2
Benefit from PMMTB recommended treatment
Whether patients benefit from PMMTB recommended treatment
Time frame
Up to 5 yearsSecondary outcomes
1
Correlation of mutations with protein overexpression
Correlate mutations identified in tumor tissue with protein overexpression
Time frame
Up to 5 years2
Correlations of mutations with circulating tumor DNA
Correlate mutations identified in tumor tissue with circulating tumor DNA
Time frame
Up to 5 years3
Correlations of mutations with spheroid culture investigations
Correlate mutations identified in tumor tissue with spheroid culture investigations
Time frame
Up to 5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Wisconsin, Madison
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov